THU0693

GOUT AND THE RISK OF PARKINSON'S DISEASE IN THE ELDERLYJ.A. Singh, J.D. Cleveland. *University of Alabama at Birmingham, Birmingham, USA*

Background: A recent systematic review and meta-analysis, based on two cohort studies and three case-control studies, reported a pooled risk ratio of subsequent Parkinson's disease (PD) in patients with gout was 0.93 (95% CI, 0.79 to 1.09), a non-significant result. However, statistical heterogeneity was high at 87%–96%, indicating that studies differed from each other. Thus, it is not clear that gout is associated with PD and if so, what is the direction and magnitude of the risk of PD with gout.

Objectives: To assess the association of gout with the risk of incident Parkinson's disease.

Methods: We used the 5% Medicare sample from 2006–2012 to assess whether a diagnosis of gout was associated with the risk of incident Parkinson's disease in the elderly. Multivariable Cox regression model adjusted for demographics, Charlson-Romano comorbidity index, common medications, allopurinol and febuxostat use, was used to obtain hazard ratios (HR) and 95% confidence interval (CI).

Results: The mean cohort age was 73 years (standard deviation [SD], 6.5), mean Charlson-Romano comorbidity index score was 1.2 (SD, 1.9), 58% were female, 86% were White and 30% had Charlson-Romano comorbidity index score of ≥ 2 ($n=15,675$). The crude incidence rates of incident PD of 3.3 vs. 1.7 per 1000 person-years in those with gout vs. without gout. Gout was associated with a higher risk of PD in the main analysis, 1.18 (95% CI, 1.10, 1.27). Older age, male gender, White race, higher Charlson-Romano comorbidity index score were associated with higher risk of PD. Sensitivity analyses confirmed main findings. No gender or race differences were noted, but the risk differed by the age; ages 65–<75, 75–<85 and ≥ 85 years were associated with hazard ratios of incident PD with gout of 1.27, 1.12 and 0.98, respectively.

Conclusions: Gout was associated with a higher risk of incident PD in the elderly. The risk of PD with gout was highest in the age group 65–75 years. Mechanisms of this increased risk need to be evaluated in future studies.

Acknowledgements: This material is the result of work supported by research funds from the Division of Rheumatology at the University of Alabama at Birmingham and the resources and use of facilities at the Birmingham VA Medical Centre, Birmingham, Alabama, USA. The funding body did not play any role in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.

Disclosure of Interest: J. Singh Grant/research support from: Takeda, Savient, Consultant for: Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC and the American College of Rheumatology, J. Cleveland: None declared

DOI: 10.1136/annrheumdis-2018-eular.7599

THU0694

THE EXCESS RISK OF DISABILITY IN PEOPLE WITH NEUROPATHIC PAIN WHEN COMPARED TO THOSE WITH NOCICEPTIVE PAIN IS EXPLAINED BY PAIN CATASTROPHISING AND PHYSICAL INACTIVITYJ. Mcbeth¹, M. Mulvey², J. Anderson¹, A. Rashid¹, K. Druce¹. ¹*Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester;* ²*Leeds University, Leeds, UK*

Background: Neuropathic pain (NP) is associated with worse patient outcomes including poorer quality of life and increased disability and mortality when compared to persons with pain that is predominantly nociceptive (NCP). It is not known if the higher rate of co-morbid psychosocial factors (e.g. depression, fatigue) in persons with NP explains the increased risk of poor outcomes.

Objectives: To test the hypotheses that pain predominantly of NP origin would be associated with higher levels of disability when compared to NCP, and the excess risk would be independent of putative confounders.

Methods: 1587 participants in a population based prospective study completed a baseline and follow up questionnaire 12 months later. Participants were asked about the presence, location and duration of musculoskeletal pain and they completed the Douleur Neuropathique 4 (scores ≥ 3 indicating NP). Participants were classified according to their pain reports as having no pain (NP), some pain with (SPn) and without (SP) NP, and chronic widespread pain American College of Rheumatology 1990 criteria) with (CWPn) and without (CWP) NP. The primary outcome was the Stanford Health Assessment Questionnaire (HAQ) from which

the Standard Disability Index (HAQ-DI) was calculated. Participants also completed the Hospital Anxiety and Depression Scale (HADS), Chalder Fatigue scale (CF); the Pain Catastrophising Scale (PCS); Rapid Assessment of Physical Activity (RAPA); Social Support scale (SS); Joint Hypermobility scale (JH); Jenkins Sleep Scale (JSS). Ordered logistic regression tested the relationship between pain status at baseline and HAQ-DI at follow up with results expressed as odds ratios (OR) with 95% confidence intervals (CI).

Results: 1235 (77%) participants provided complete data and formed the cohort for this analysis. At 12 month follow up the mean (standard deviation) HAQ-DI score was 0.31 (0.62), with higher scores in women and older participants. After adjusting for age and sex, when compared to those with NP at baseline participants with SP were 3 times (OR=2.9, 95% CI (2.2, 3.9)) and those with SPn almost 9 times (8.7 (5.4, 14.0)) more likely to have higher HAQ-DI scores at follow up. Those with CWP were 8 (7.8 (5.7, 10.8)) and those with CWPn 38 (38.1 (23.3, 62.5)) times more likely to have higher HAQ-DI scores. When these associations were adjusted for putative confounders and baseline HAQ-DI scores having pain remained associated with increased HAQ-DI scores at follow up although the relationships were significantly attenuated, and the 95% CIs were similar across pain groups: SP 1.8 (1.3, 2.5); SPn 2.6 (1.4, 4.8); CWP 2.3 (1.6, 3.4); 3.3 (1.9, 6.0). The PCS helplessness scale (1.07 (1.01, 1.13)) and RAPA (0.93 (0.87, 0.99)) were significantly associated with 12 month HAQ-DI scores.

Conclusions: The increased risk of disability in persons with NP was not independent of common pain co-morbidities. Screening and targeting treatment for pain-related helplessness and physical inactivity has the potential to significantly improve disability outcomes for persons with NP.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5935

THU0695

DOES HORMONE REPLACEMENT THERAPY PREVENT UNDIFFERENTIATED ARTHRITIS PROGRESSING TO RHEUMATOID ARTHRITISK. Miyachi^{1,2}, A. Ihara³, B. Sasse⁴. ¹*Rheumatology and Women's Health, Keigu Clinic;* ²*The Technological Development, Health Sciences Research Institute;* ³*Rheumatology, Keigu Clinic, Yokohama, Japan;* ⁴*Rheumatology, Monash Health, Victoria, Australia*

Background: Oral contraceptive (OC) and hormone replacement therapy (HRT) have been reported to have a protective and preventive effect on the progression of rheumatoid arthritis (RA). Although these observations are controversial, progression of undifferentiated arthritis (UA) to RA in pre- and post-menopausal women is largely unreported.

Objectives: Over a 10 year period, we followed patients with undifferentiated arthritis (UA) who were referred to rheumatologists and did not fulfil classification or diagnostic criteria for RA or other connective tissue disease. We studied the efficacy of hormone replacement therapy (HRT) in this setting. In this study, the primary objective was to determine whether HRT reduces joint pain and/or decreased the progression of UA to RA.

Methods: From 2007 to 2016, 1076 patients (male:60, female:1016) classified as UA were referred to one of two clinics because of complaints of joint pains and were enrolled in this study. Beginning in 2012, premenstrual, perimenstrual and postmenstrual women with UA were prescribed ultra-low dose tocopherol (600 mg/day) and HRT. A reduction of over 70% joint pain on a p-visual analogue scale (p-VAS) was set as the criterion of a favourable outcome. Each patient was assigned into one primary disease category. For example, primary SjS was regarded as a disease category but if a patient had secondary SjS, they were assigned to the primary (RA, SLE, SSC) disease category.

Results: During the 5 year observation period, 213/343 (62.1%) had postmenopausal arthralgia (PoMA), 46/112 (41.1%) with perimenopausal arthralgia (PeMA), 17/25 (68%) with premenopausal arthralgia (PrMA). In the RA patients, 10.2%, had RF alone, 73.1% (250/342) had ACPA and/or RF or ACPA alone and 16.7% had neither ACPA or RF. The specificity of ACPA was 93.2%. Regarding efficacy of HRT, the incidence of RA in RF positive individuals was 9.1% (5/55) in patients undergoing HRT (current and past user), which was significantly lower ($p<0.01$) than the 48.4% (30/62) in those never treated with HRT. Likely due to low numbers in the cohort, the incidence of RA in ACPA positive females was 22.2% (2/9) in those receiving HRT was not statistically significantly lower than the 70% (7/10) in those with without HRT.

Figure 1 Postmenopausal women responded to conventional HRT in 2013–2015

Conclusions: The progression of UA to RA is apparently ameliorated in RF positive females who received conventional HRT and oral E3 treatment. Although the numbers were smaller, a significant protective effect was not observed in ACPA positive UA females, because they developed RA before menopause. Our observations suggest that HRT in peri- and post-menopausal and oestrogen (E3) in pre-menopausal females with RF and ACPA positive UA may be important in ameliorating the progression of UA to RA.

REFERENCES:

- Orellana C, Saevarsdottir S, Klareskog L, Karlson EW, Alfredsson L, Bengtsson C. Postmenopausal hormone therapy and the risk of rheumatoid arthritis: results from the Swedish EIRA population-based case-control study. *Eur J Epidemiol* 2015;30(5):449–57.
- Walitt B, Pettinger M, Weinstein A, Katz J, Torner J, Wasko MC, et al. Walitt B, Pettinger M, Weinstein A, et al. Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. *Arthritis Rheum* 2008;59(3):302–10.

Acknowledgements: We thank Dr Koyama for his advices and encouragement.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4077

THU0696 IS AUTOIMMUNITY RELATED TO NAILFOLD VIDEOCAPILLAROSCOPY PATTERNS PROGRESSION? DATA FROM A TERTIARY CENTRE

L. Torrens, C. Soletto, J.C. Nieto-González, on behalf of Dra. Alicia Silva, Dra Ana López-Cerón; Dr. Juan G. Ovalles-Bonilla, Dra. Iustina Janta, Dra. Claudia Sáenz, Dr. Carlos M. González, Dr. Indalecio Monteagudo. *Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain*

Background: Nailfold videocapillaroscopy (NVC) is a non-invasive technique that allows to evaluate the structure and distribution of capillaries in the nail microcirculation.

Objectives: Our objective was to investigate the relation between the autoantibodies (Ab) detected in the patients who undergo follow-up NVCs and the progression from lower to higher severity of the NVCs patterns.

Methods: Longitudinal, observational and descriptive study that includes patients with at least two NVCs, between June 2012 and December 2016 in the Rheumatology service of a tertiary centre. We collected demographics data, number of NVCs performed, Ab positivity, as well as the NVCs patterns. The relationship between the basal autoimmunity and the progression of the NVCs patterns during the follow-up period, defining progression from non-specific patterns to patterns of scleroderma to late scleroderma.

Results: 473 patients were included, 115 had two or more NVCs performed, 104 women (90.51%). Of these, 40 (34.78%) had a third NVC, 9 (7.82%) a fourth and only two patients a fifth. Regarding the Ab registered in patients before the first NVC, 27 patients did not present positivity to any Ab (23.47%), 28 had isolated ANA + (24.34%), 33 Anticentromere+with or without ANA (28.69%), 7 patients Anti-scl70 +with or without ANA (6.08%), 10 patients Anti-Ro or Anti-La with or without ANA (8.69) and 10 patients presented other types of antibodies than those mentioned (11.3%). The most frequent pattern in the first NVC was non-specific mild alterations (49 cases) in 42.6%, followed by normal pattern²⁰ in 17.39%, early scleroderma¹⁹ in 16.52%, non-specific moderate lesions¹⁷ and pattern of late scleroderma¹⁰ There was a progression from lower to higher severity in 25 NVCs,

88 maintained a similar pattern and 2 NVCs presented significant regression (table 2).

Abstract THU0696 – Table 1. Baseline diagnosis before first NVC.

Baseline diagnosis	n: 115	%
Primary Raynaud Phenomenon	56	48.27
Systemic scleroderma	27	23.27
Systemic Lupus Erythematosus	8	6.89
Undifferentiated connective tissue	8	6.89
Mixed Connective Tissue Disease	4	4.31
Dermatomyositis	2	1.72
Others	10	8.62

Abstract THU0696 – Table 2. Patients whose NVC progresses, patterns and related autoantibodies.

n:25 (%)	Autoantibodies	Progression
2 (8%)	Ninguno	1/2: NMI to ES, 1/2: NMI to LS
4 (16%)	ANA+	2/4: NMI to AS, 1/4: NMI to AS, 1/4: NMI to ES
10 (40%)	ANA ± Anticentromero +	3/10: AS to LS, 3/10: ES to LS, 2/10: NMI to ES, 1/10: NMI to AS
3 (12%)	ANA±AntiScl70 +	1/3: NMI to AS, 1/3: AS to LS, 1/3: ES to AS
3 (12%)	ANA±Anti-Ro/ Anti-La+	2/3: NMI to ES, 1/3: ES to LS
3 (12%)	Otros	2/3: ES to LS, 1/3: NMI to LS

NVC patterns: Normal (N), non-specific mild alterations (NMI), non-specific moderate lesions (NML), Early scleroderma (ES), Active scleroderma (AS) y Late scleroderma (LS)

Conclusions: Autoimmunity does not seem to influence on the degree of progression of NVCs patterns. The association between positive ANA with anticentromere + or not, it is the most frequently combination related to the progression of such patterns.

REFERENCES:

- Cutolo M, Pizzorni C, Secchi ME, Sulli A. Capillaroscopy. *Best Pract Res Clin Rheumatol* 2008 Dec;22(6):1093-108

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7115

THU0697 RISK OF MAJOR CONGENITAL MALFORMATIONS ASSOCIATED WITH EXPOSURE TO CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN WOMEN WITH INFLAMMATORY ARTHRITIS: A POPULATION-BASED COHORT STUDY

M.A. De Vera^{1,2}, E.C. Sayre², N.W. Tsao^{1,2}, A. Howren¹. ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, ²Arthritis Research Canada, Richmond, Canada

Background: Prior studies of perinatal exposure to conventional synthetic disease modifying antirheumatic drugs (csDMARDs) and risk of major congenital malformations (MCM) have often lacked comparator groups and specific timing of medication exposure.

Objectives: To evaluate the association between csDMARD use before and during pregnancy and risk of MCM.

Methods: We conducted a population-based, retrospective cohort study using British Columbia administrative data from 01/01/2002 and 12/31/2012 on all physician visits, hospital admissions, and dispensed medications, linked to a perinatal registry with valid information on date of conception. We created a pregnancy cohort of women with inflammatory arthritis (IA) using a case definition of 2 ICD9 codes ≥2 months and ≤2 years apart for rheumatoid arthritis, systemic autoimmune rheumatic diseases, ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis. We categorised csDMARDs according to accepted safety profiles: Group 1 - antimalarials, cyclosporine-A, gold, and sulfasalazine; and Group 2 - methotrexate, leflunomide, cyclophosphamide, azathioprine, chlorambucil, penicillamine, mycophenolate mofetil, and minocycline. We defined exposure over two periods: binary use (yes/no) during the 90 days preconception and first trimester of pregnancy. The outcome was occurrence of ≥1 MCM identified